Navigation Links
US Government Awards Contract to Bavarian Nordic for the Development of Freeze-Dried IMVAMUNE(R) Smallpox Vaccine

KVISTGARD, Denmark, November 17 /PRNewswire-FirstCall/ -- Bavarian Nordic A/S (OMX: BAVA) announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.

The contract provides funds to validate the new freeze-dried manufacturing process and the associated pre-clinical and clinical studies to support the advanced development of a freeze-dried version of IMVAMUNE(R). The base year funding represents 33% of the total contract value, followed by four additional years of optional funding, which are triggered by the completion of pre-determined technical milestones. These freeze-dried development activities will be performed in parallel to the licensure activities of the current liquid-frozen IMVAMUNE(R) formulation under the RFP-3 contract.

The contract does not affect the company's expectations for the 2009 full year results.

With this contract, the US Government has to-date awarded contracts to Bavarian Nordic for the development and procurement of IMVAMUNE(R) worth more than USD 680 million. Under the ongoing RFP 3 contract, Bavarian Nordic will deliver 20 million doses of IMVAMUNE(R) in the current liquid-frozen formulation. Once the contract option for an additional 60 million doses is expectedly exercised, these vaccines will be delivered in the liquid-frozen formulation as well. Thus, the new contract will have no influence on the ongoing contracts, but represents an additional business opportunity and will expectedly constitute the gateway towards securing additional contracts for this new freeze-dried version with the US Government and outside the US as well.

A freeze-dried formulation of IMVAMUNE(R) offers various new advantages in terms of a potential increased shelf-life compared to the current liquid-frozen formulation. Additionally, this would help overcome the challenges with the cold-chain logistics and storage.

Anders Hedegaard, President & CEO of Bavarian Nordic said: "We are excited about receiving yet another contract from the US Government in support for the development of an advanced freeze-dried version of our IMVAMUNE(R) smallpox vaccine. It clearly demonstrates the continued commitment from the US Government to support the development of advanced medical countermeasures and it strengthens our confidence, that the option to procure up to an additional 60 million doses of IMVAMUNE(R) under the ongoing RFP-3 contract will be exercised."

Forward-looking statements

This announcement includes "forward-looking statements" that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

About Bavarian Nordic

Bavarian Nordic A/S is a leading industrial biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's pipeline is focused in the three areas; biodefence, cancer and infectious diseases, and includes seven development programmes. Two programmes are ready for Phase III: IMVAMUNE(R), a third-generation smallpox vaccine is being developed under a contract with the US government, and PROSTVAC(TM), a therapeutic vaccine for advanced prostate cancer is being developed under a collaboration agreement with the National Cancer Institute.

Bavarian Nordic is listed on NASDAQ OMX Copenhagen under the symbol BAVA.

For more information please visit

SOURCE Bavarian Nordic A/S

SOURCE Bavarian Nordic A/S
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. GeneNews CSO Dr. CC Liew awarded state honour by the Government of Malaysia
2. The Government of Quebec and the New Canadian Government Invest in the Creation of an International Biobank
3. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
4. Isis Announces $4.2 Million in Government Contracts Awarded to Its Ibis Subsidiary for Biodefense Applications Development
5. U.S. Government Awards $15 Million Grant to GeoVax Labs HIV/AIDS Vaccine Program
6. Sales of Etimicin Sulfate to Expand Nationwide as Government Restriction is Lifted
7. Government Expands Trial With IMVAMUNE(R) Smallpox Vaccine in Persons With Atopic Dermatitis/Eczema
8. Implicit Awarded US $16.3 Million U.S. Government Contract to Develop Immunomodulatory Drug for Biodefense Threats
9. Biomoda Hires Manzano Strategies LLC to Spearhead Government Affairs Efforts
10. Sirnaomics Received Multiple Government Fundings For Its Multi-Targeted siRNA Therapeutics Programs
11. Aida Receives Chinese Government Innovation Award
Post Your Comments:
(Date:11/24/2015)... -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ) today announced ... chief executive officer, will present at the 27 th ... New York City . The presentation will be webcast ... 9:30 a.m. EST. and go to ... 15 minutes prior to the presentation to allow for any ...
(Date:11/24/2015)... 24, 2015 According to two new studies, fewer ... is something that many doctors, scientists, and public health experts ... with fewer PSA tests being done, will there be more ... Dr. David Samadi, "Despite the efforts made in regards ... second leading cancer cause of death in men, killing approximately ...
(Date:11/23/2015)... 23, 2015 China Cord Blood Corporation (NYSE: ... provider of cord blood collection, laboratory testing, hematopoietic stem ... its preliminary unaudited financial results for the second quarter ... 30, 2015. --> --> ... Revenues for the second quarter of fiscal 2016 increased ...
(Date:11/23/2015)... GENEVA , November 23, 2015 ... to develop daclatasvir for 112 ... countries   --> --> ... licence for a hepatitis C medicine, signing an agreement with ... proven to help cure multiple genotypes of the HCV virus. ...
Breaking Biology Technology:
(Date:11/18/2015)... 18, 2015 --> ... new market report titled  Gesture Recognition Market - Global ... - 2021. According to the report, the global gesture recognition market was ... to reach US$29.1 bn by 2021, at a CAGR ... North America dominated the global gesture recognition ...
(Date:11/17/2015)... , Nov. 17, 2015 Pressure BioSciences, Inc. ... the development and sale of broadly enabling, pressure cycling ... sciences industry, today announced it has received gross proceeds ... million Private Placement (the "Offering"), increasing the total amount ... or more additional closings are expected in the near ...
(Date:11/12/2015)... 11, 2015   Growing need for low-cost, ... has been paving the way for use of ... discrete analytes in clinical, agricultural, environmental, food and ... used in medical applications, however, their adoption is ... to continuous emphasis on improving product quality and ...
Breaking Biology News(10 mins):